BNP Paribas Asset Management
GBT

BNP Paribas Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

BNP Paribas Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-284,891
Closed -$19.4M – 936
2022
Q3 		$19.4M Sell
284,891
-666,220
-70% -$36.7M 0.08% 285
2022
Q2 		$30.4M Buy
951,111
+308,207
+48% +$9.02M 0.12% 205
2022
Q1 		$22.3M Buy
642,904
+242,117
+60% +$7.24M 0.08% 285
2021
Q4 		$11.7M Buy
400,787
+86,714
+28% +$2.69M 0.04% 419
2021
Q3 		$8M Sell
314,073
-274,848
-47% -$8.08M 0.03% 452
2021
Q2 		$20.6M Buy
588,921
+52,099
+10% +$2.03M 0.07% 307
2021
Q1 		$21.9M Buy
536,822
+278,667
+108% +$12.8M 0.09% 263
2020
Q4 		$11.2M Sell
258,155
-42,558
-14% -$2.1M 0.05% 363
2020
Q3 		$16.6M Buy
300,713
+66,695
+28% +$4.24M 0.09% 245
2020
Q2 		$14.8M Buy
+234,018
New +$16.1M 0.1% 236

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BNP Paribas Asset Management's GBT Position: Q4 2022 in Review

BNP Paribas Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 284,891 shares — an estimated $19.4M sold.

BNP Paribas Asset Management first reported a position in GBT in Q2 2020 and held it in 10 quarters. The position peaked at $30.4M in Q2 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • BNP Paribas Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Asset Management sold 284,891 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $19.4M.
  • BNP Paribas Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 10 quarters.
  • BNP Paribas Asset Management's Global Blood Therapeutics, Inc. position peaked at $30.4M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on BNP Paribas Asset Management's 13F filing for Q4 2022, filed 10 Feb 2023.